Equillium, Inc. (EQ)
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.
Address
2223 AVENIDA DE LA PLAYA
LA JOLLA, CA 92037
Founded
2017
Number of Employees
44
Website
http://www.equilliumbio.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | - | $251 | - | $251 |
| Average Price | - | - | - | - | - | - | - | - | - | $0.84 | - | $0.84 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 298,385 | - | 298,385 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 19.0% | - | 19.0% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.9% | - | 31.9% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | -12.8% | - | -12.8% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 57% | - | 54% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at EQ make a trade.
Creating a free account takes less than one minute